Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

SQ Innovation announced that the Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System (HCPCS) Level II code, J1946 ("Injection, furosemide (Lasix ONYU), 1 mg"), for its product Lasix® ONYU...

Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

Parents looking for an infant formula made with whole milk now have a new option. Abbott announced the launch of Similac® 360 Total Care Made With Whole Milk—the first and only commercially sterile, ready-to-feed liquid infant formula made with...

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive...

Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

Dunbar Pharmaceuticals Ireland's first EU GMP-certified manufacturer of plant-derived cannabinoid active pharmaceutical ingredients (APIs), announced that its plant-derived dronabinol API, WaterClear THC™, is now available across the United...

Former DePuy Synthes U.S. President Joins Peptilogics Board

Tim Czartoski, orthopedic executive and former president of DePuy Synthes U.S. and most recently president of U.S. Surgical and Global R&D at Enovis, has joined the Peptilogics board of directors. His background in leading large orthopedic device...

Bruker and Atinary Technologies Join Forces to Accelerate the Future of Self-Driving Laboratories

Bruker Corporation announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technologies and AI-driven R&D with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also...

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent...

Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

Triquetra Health, a clinical-grade supplement company specializing in evidence-based formulation, announced the launch of BioActive Vitamin B1™ Clinical Strength, a complete B1 activation system delivering 600mg benfotiamine at the...

InstaMed® Pharmaceuticals Appoints Tracy Gibbs, PhD, as Chief Executive Officer Ahead of the Worldwide Launch of Its Non-Injectable Peptide Platform

InstaMed® Pharmaceuticals, an advanced biotechnology company transforming peptide delivery through its patented InstaRelease® oral dissolving strip platform, announced the appointment of Tracy Gibbs, PhD, as Chief Executive Officer. The leadership...

Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Merck, a leading global science and technology company, announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with...

FDA Approves Expanded Indication for Octapharma USA's wilate® for Prophylaxis of von Willebrand Disease in Children Younger Than 6 Years

On July 2, 2026, the U.S. Food and Drug Administration (FDA) approved the use of wilate® (von Willebrand Factor/Coagulation Factor VIII Complex [Human]) for routine prophylaxis to reduce the frequency of bleeding episodes in pediatric patients...

Cannabix Technologies and Omega Laboratories Announce a DOT-Like Breath-Based Drug Testing Panel for Recent-Use Detection

Omega Laboratories, Inc. ("Omega"), and Cannabix Technologies Inc. announce the development and validation of a DOT-like drug-test panel for breath testing. The validated laboratory method expands Omega's breath-testing capability beyond...

Eligible Medicare Beneficiaries Living with Obesity Can Now Access Wegovy® Through the Medicare GLP-1 Bridge

Starting today FDA-approved Wegovy® (semaglutide) is available through the Medicare GLP-1 Bridge, a new access pathway for millions of older adults living with obesity. Obesity is a serious, common chronic disease among older Americans and Wegovy®...

Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX) today announced the launch of KYMBEE™ (deflazacort) Oral Suspension, 22.75 mg/mL indicated for the treatment of Duchenne...

Strong Performance Across More Than 200 Customer Audits Highlighted by Piramal Pharma Solutions

Piramal Pharma Solutions a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. announced that it completed more than 200 customer audits and received over 70 approvals from regulatory agencies...

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

ELASTEN®, Germany's 1 liquid collagen supplement and a global leader in clinically studied ingestible skincare, announced a year-long partnership with renowned board-certified dermatologist, media expert, and trusted authority in cosmetic and...

SEREMI de Salud Grants Registration to Chile's First Finished Product Featuring Setria® Glutathione

Kyowa Hakko, a global leader in health ingredient innovation and manufacturer of branded ingredient Setria® Glutathione, announced that a supplement featuring Setria has been approved for sale in Chile through the Secretaría Regional Ministerial...

Greater Stability and Control for Everyday Injections: Ascensia Diabetes Care Expands the CONTOUR® Portfolio with CONTOUR® COMFORT Pen Needles

Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (TSE 6523), announced the launch of CONTOUR®COMFORT pen needles, further strengthening its CONTOUR® portfolio with a solution that improves the...

XOCOVA® Becomes First Oral Option for Post-Exposure COVID-19 Prevention

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that the U.S. Food and Drug Administration (FDA) has approved XOCOVA® (ensitrelvir), an oral antiviral, for...

BrainStorm Cell Therapeutics appoints Peter J. Pitts to its board.

BrainStorm Cell Therapeutics Inc. a leading developer of autologous stem cell therapies for neurodegenerative diseases, announced that Peter J. Pitts has been appointed to the Company's Board of Directors, effective immediately. Mr. Pitts is a...